pharma
dog
News
when
Latest
Archive
by source
All Sources
Sources Page
Jobs
department
Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access
therapeutic area
Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease
location & type
Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →
Drugs
by stage
Marketed
Phase 3
Phase 2
Phase 1
Preclinical
browse
Most catalysts
Recently active
All drugs →
Companies
Patent cliff
Calendar
what
Trial readouts
PDUFA dates
Approvals
Earnings
when
Upcoming
Month grid
Recently passed
◐
Sign In
Subscribe
home
jobs
news
search
Bispecific Antibody · news · pharmadog
← back to Bispecific Antibody
News · Bispecific Antibody
209
stories
21d
Cellectis quits CAR-T and pivots to ‘in vivo’ gene editing
biopharma dive
21d
Summit, BioNTech, more headline WCLC with next-gen lung cancer drugs
biospace
22d
Cellectis cans allogeneic CAR-Ts to hop aboard in vivo bandwagon
fiercebiotech
22d
Unlocking cell surface protein research with site-specific labeling
biospace
23d
Akeso details survival win for its PD-1xVEGF drug versus Keytruda
endpoints
24d
Cullinan, Taiho showcase 6-month survival benefit in phase 3 trial for advanced lung cancer
fiercebiotech
27d
Beyond China: Five other overseas destinations for biopharma dollars
biospace
28d
Bristol Myers’ pivotal CAR-T multiple myeloma trial hits primary endpoint
fiercebiotech
Sep 4, 26
Trailing rivals, AbbVie scores win with dual-acting myeloma drug
biopharma dive
Sep 4, 26
AbbVie’s T cell engager delivers survival benefit in Phase 3 multiple myeloma study
biospace
Sep 3, 26
Summit, Akeso’s ivonescimab bests Merck’s Keytruda in China trial—again
biospace
Sep 3, 26
Akeso, Summit cancer drug confirms lung cancer survival benefit
biopharma dive
Sep 3, 26
Summit, Akeso say ivonescimab clears OS bar in Phase 3 lung cancer trial
endpoints
Sep 3, 26
AbbVie’s bispecific T-cell engager shows promise in ph. 3 multiple myeloma trial
fiercebiotech
Sep 2, 26
Stripped of AstraZeneca safety net, BMS could face ‘carnage’ if high-risk clinical trial fails
biospace
Sep 1, 26
Roche inks $1.53B deal for Simcere’s B-cell-targeting antibody
fiercebiotech
Aug 28, 26
Multispecifics are transforming the CDMO development architecture
biospace
Aug 28, 26
Genentech doubles down on ADC-resistant cancers with $1B DualityBio pact
fiercebiotech
Aug 27, 26
Q&A: Akeso CEO spells out why she thinks its biliary tract cancer data are a big deal
endpoints
Aug 26, 26
Summit, Akeso tout biliary cancer win for PD-1/VEGF in China—but details are pending
biospace
Aug 26, 26
Jazz scores front-line gastric cancer nod from FDA for ‘practice-changing’ Ziihera
biospace
Aug 26, 26
Akeso, Summit hail ivonescimab's biliary tract cancer win in China-only Phase 3 trial
endpoints
Aug 26, 26
Akeso CEO looks beyond lung cancer with biliary tract win, counters ivonescimab debate
fiercebiotech
Aug 25, 26
FDA approves Jazz's Ziihera in frontline gastric cancer
endpoints
Aug 20, 26
Chai tees up Bristol Myers Squibb AI antibody discovery collab
fiercebiotech
Aug 20, 26
Why Pheast’s CEO has no regrets about transparent approach to R&D despite competitors circling
fiercebiotech
Aug 19, 26
Bristol Myers' partner Biokin says bispecific ADC clears fourth cancer trial in China
endpoints
Aug 19, 26
Amylyx’s redemption story, Summit’s survival woes, Definium’s anxiety win, more
biospace
Aug 17, 26
AstraZeneca scraps Phase 3 trial of new bispecific in lung cancer
biopharma dive
Aug 17, 26
Summit, Akeso's ivonescimab shows smaller benefit with longer follow-up in China
endpoints
← prev
page 2 of 7
next →
